IE
CMMB

Israel Englander’s Chemomab Therapeutics CMMB Stock Holding History

Israel Englander’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,641
Closed -$16.6K – 6017
2024
Q3 		$16.6K Buy
+2,641
New +$14.8K ﹤0.01% 5815
2024
Q1 		– Sell
-4,925
Closed -$10K – 6230
2023
Q4 		$10K Buy
+4,925
New +$13K ﹤0.01% 5740

Other funds holding CMMB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $527M AUM 50.16% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Israel Englander's CMMB Position: Q4 2024 in Review

Israel Englander sold out of Chemomab Therapeutics (CMMB) in Q4 2024, closing a stake of 2,641 shares — an estimated $16.6K sold.

Israel Englander first reported a position in CMMB in Q4 2023 and held it in 2 quarters. The position peaked at $16.6K in Q3 2024. 16 funds tracked by Wall St. Rank hold CMMB as of Q4 2024.

  • Israel Englander reported no remaining Chemomab Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Israel Englander sold 2,641 Chemomab Therapeutics shares in Q4 2024, an estimated $16.6K.
  • Israel Englander first reported a position in Chemomab Therapeutics in Q4 2023 and held it in 2 quarters.
  • Israel Englander's Chemomab Therapeutics position peaked at $16.6K in Q3 2024.
  • 16 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q4 2024.

Based on Millennium Management's 13F filing for Q4 2024, filed 14 Feb 2025.